Compare CASH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | URGN |
|---|---|---|
| Founded | 1954 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1996 | 2016 |
| Metric | CASH | URGN |
|---|---|---|
| Price | $91.14 | $39.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $107.50 | $29.29 |
| AVG Volume (30 Days) | 195.0K | ★ 717.0K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $839,894,000.00 | $1,128,000.00 |
| Revenue This Year | $7.56 | $129.09 |
| Revenue Next Year | $6.02 | $70.96 |
| P/E Ratio | $18.56 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $65.93 | $15.86 |
| 52 Week High | $101.26 | $43.93 |
| Indicator | CASH | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | N/A |
| Support Level | $86.45 | N/A |
| Resistance Level | $94.61 | N/A |
| Average True Range (ATR) | 2.49 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 82.42 | 0.00 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.